J&J, Bayer Fail to Win U.S. Backing for Expanded Xarelto

Johnson & Johnson and Bayer AG failed to win approval to expand use of their blood thinner Xarelto to prevent heart attacks and strokes in patients with serious chest pain or history of cardiac illness.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.